FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial resu...
Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expend...
Sanara MedTech's surgical revenue grew 26% year-over-year in Q1, with a gross margin of 92%. Surgical adjusted EBITDA was $2.7 million in Q1, while THP correspondingly posted a loss of $2 million. High debt levels and elevated interest expenses are key risks, along with the uncertainty surrounding the commercialization of THP.
Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman, Chief Executive Officer Seth Yon - President, Chief Commercial Officer Sam Muppalla - President, Chief Executive Officer of Tissue Health Plus Elizabeth Taylor - Chief Financial Officer Conference Call Participants Matt Park - Cantor Fitzgerald Operato...
Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today...
FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial ...
FORT WORTH, TX, April 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that management will present at...
Sanara MedTech Inc. (NASDAQ:SMTI ) Q4 2024 Earnings Conference Call March 25, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman and Chief Executive Officer Seth Yon - President, Commercial Sam Muppalla - Tissue Health Plus Tyler Palmer - Chief Corporate Development and Strategy Officer Elizabeth Taylor - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.